Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global HUMIRA (Adalimumab Drug) Market Size: By Indication: Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn’s Disease, Ulcerative Colitis, Psoriatic Arthritis, Others; By Type; By Dosage Strength; By Drug Type; By Route of Administration; By Distribution Channels; Regional Analysis; Supplier Landscape; 2023-2031

Global HUMIRA (Adalimumab Drug) Market Outlook

The rising case of rheumatoid arthritis drives the growth of the global HUMIRA (adalimumab drug) market. The number of rheumatoid arthritis disease cases was 35 million in 2021. The overall market is likely to grow at a CAGR of 1% in the forecast period of 2023-2031. With this growth rate, the number of cases is likely to reach nearly 38.3 million by 2030.

 

Introduction

Adalimumab is a monoclonal antibody and disease-modifying anti-rheumatic drug that works by inactivating tumour necrosis factor alpha.

 

HUMIRA and Exemptia are two of its brand names. The original brand name of adalimumab drug is HUMIRA. The adalimumab biosimilar is the latest version of adalimumab. The biosimilar form of a biological medicine is the same as the original form. It is used to treat conditions such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and suppurative rhinitis.

 

The growth of HUMIRA (adalimumab drug) market is influenced by several factors, including the prevalence of arthritis and skin diseases, sedentary lifestyles, and the growing obesity population.

 

According to the research report, the market can be categorised into the following segments:

 

Market Breakup by Indication

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Chronic Plaque Psoriasis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Psoriatic Arthritis
  • Others

 

Market Breakup by Type

  • Biologics
  • Biosimilars
  • Adalimumab-ATTO
  • Adalimumab-BWWD
  • Adalimumab-ADBM
  • Adalimumab-ADAZ
  • Adalimumab-FKJP
  • Adalimumab-AFZB
  • Others

 

Market Breakup by Dosage Strength

  • 40MG/0.4ML
  • 80MG/0.8ML
  • 20MG/0.4ML
  • 10MG/0.1ML
  • Others

 

Market Breakup by Drug Type

  • Branded
  • Generics
  • Amjevita
  • Hyrimoz
  • Hulio
  • Others

 

Market Breakup by Distribution Channels

  • Hospital Based Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

 

Market Breakup by Route of Administration

  • Parenteral
  • Oral
  • Others

 

Market Breakup by Region

  • North America

United States of America

Canada

  • Europe

United Kingdom

Germany

France

Italy

Others

  • Asia Pacific

China

Japan

India

ASEAN

Australia

Others

  • Latin America

Brazil

Argentina

Mexico

Others

  • Middle East and Africa

Saudi Arabia

United Arab Emirates

Nigeria

South Africa

Others

 

Market Scenario

The rapidly growing cases of arthritis are propelling the demand for HUMIRA (adalimumab drug) market. This is largely a result of the increasing number of elderly people. Women are more likely to develop arthritis as they age since their bodies lose calcium.

 

The development of arthritis and psoriasis is linked to sedentary lifestyles. The drug is majorly consumed based on both of these factors. The HUMIRA (adalimumab drug) market is expected to grow further due to improvements in disease diagnostics and strong support for effective biopharmaceuticals.

 

HUMIRA (adalimumab drug) is an expensive drug due to its biological properties. A factor limiting the growth of the HUMIRA (adalimumab drug) market is the price of the therapy, which can be upto USD 5,000 per month. It remains a challenge for the market to handle the high cost of treatment procedures.

 

Furthermore, the arrival of new technologies and various therapeutic procedures aimed at benefiting end-users is likely to stimulate the  global HUMIRA (adalimumab drug) market.

 

Increasing government investments are increasing the growth prospects of the global HUMIRA (adalimumab drug) market. The blockbuster drug's patent expiration has also provided new opportunities for major market players due to the entry of HUMIRA (adalimumab drug) into the market.

 

Also, HUMIRA (adalimumab drug) market growth will be slowed in part by the lack of qualified specialists to treat this disease with the right preparations.

 

Regional Outlook for HUMIRA (Adalimumab Drug) Market

Geographically, North America is the biggest market for innovative medicines that feature the newest technological advancements. The global HUMIRA (adalimumab drug) market growth rate is also being driven by factors such as availability of advanced medical equipment, technological advancements, and launches of many innovative drugs.

 

The fastest-growing market during the forecast period will be Asia Pacific due to increasing popularity and rising healthcare expenditure. A favourable regulatory policy for biosimilars is expected to boost the demand for HUMIRA (adalimumab drug) over the forecast period.

 

Therapeutic Landscape

It is possible to use HUMIRA drugs as therapeutic platforms to treat a wide range of conditions. HUMIRA drugs have clinical applications in the treatment of various diseases.

 

HUMIRA (Adalimumab) is a monoclonal antibody designed to inhibit the effects of human tumor necrosis factor. HUMIRA contains heavy and light chains of human IgG1k with variable and constant regions.

 

A recombinant DNA technology is used to produce adalimumab in Chinese hamster ovary cells. Injections are prepared from it. This antibody binds specifically to TNF-α and blocks its interaction with the cell surface TNF receptors p55 and p75.

 

TNF is a naturally occurring cytokine that plays a role in the immune and inflammatory response of the body. One of the most important cytokines is tumor necrosis factor alpha. It plays an important role in the inflammatory chain reaction.

 

TNF modulates biological responses such as changes in adhesion molecules related to leukocyte migration when adalimumab is administered. Adalimumab is effective against autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis vulgaris due to its anti-TNF effects.

 

Clinical Trial

A number of diseases relating to the musculoskeletal system are associated with HUMIRA, such as arthritis, psoriasis, and arthritic conditions. HUMIRA drugs have therapeutic potential to control many diseases.

 

Numerous studies are being conducted to determine how HUMIRA can be used to treat and diagnose a variety of diseases. Various new drugs have appeared on the market, such as:

 

  • The toxin-binding subunit of IBI303 is the same amino acid sequence as the brand name HUMIRA (adalimumab), which is highly similar to this antibody. The study results have indicated that IBI303 can significantly relieve physical symptoms, reduce disease activity, and decrease inflammation in patients while improving their physical motor skills and spinal mobility.
  • CT-P17 is the first HUMIRA biosimilar to be highly concentrated. A half-dose was used to distinguish CT-P17 from HUMIRA's biosimilar. Additionally, Celltrion has removed citrate from its latest product, a compound that can create pain during self-injection.

 

All these emerging drugs will drive the global HUMIRA (Adalimumab drug) market.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global HUMIRA (Adalimumab drug) market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • AbbVie Inc.
  • Amgen Inc.
  • Fresenius Kabi AG
  • Celltrion Healthcare Co Ltd
  • Alvotech Ehf.
  • Bio-Thera Solutions Ltd.
  • Zydus Lifesciences Limited
  • Hetero Healthcare Ltd.
  • Innovent Biologics, Inc.
  • Novartis International AG

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2016-2022
Forecast Period 2023-2031
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Indication
  • Type
  • Dosage Strength
  • Drug Type
  • Route of Administration
  • Distribution Channels
  • Region
Breakup by Indication
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Chronic Plaque Psoriasis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Psoriatic Arthritis
  • Others
Breakup by Type
  • Biologics
  • Biosimilars
    • Adalimumab-ATTO
    • Adalimumab-BWWD
    • Adalimumab-ADBM
    •  Adalimumab-ADAZ
    • Adalimumab-FKJP
    • Adalimumab-AFZB
    • Others
Breakup by Dosage Strength
  • 40MG/0.4ML
  • 80MG/0.8ML
  • 20MG/0.4ML
  • 10MG/0.1ML
  • Others
Breakup by Drug Type
  • Branded
  • Generics
    • Amjevita
    • Hyrimoz
    • Hulio
    • Others
Breakup by Route of Administration
  • Parenteral
  • Oral
  • Others
Breakup by Distribution Channels
  • Hospital Based Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • AbbVie Inc.
  • Amgen Inc.
  • Fresenius Kabi AG 
  • Celltrion Healthcare Co Ltd
  • Alvotech Ehf.
  • Bio-Thera Solutions Ltd.
  • Zydus Lifesciences Limited
  • Hetero Healthcare Ltd.
  • Innovent Biologics, Inc.
  • Novartis International AG (Sandoz)
  • Reliance Life Sciences Pvt. Ltd.
  • Samsung C&T Corporation
  • Terumo Corp.
  • Torrent Pharmaceuticals Ltd.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
        1.1.1    Research Objectives
        1.1.2    Key Findings of the Report
    1.2    Limitations of the Study and Scope for Future Research
2    Research Methodology
3    Executive Summary
4    Global Humira (Adalimumab) Drug Overview

    4.1    Drug Overview
        4.1.1    Pharmacodynamics
        4.1.2    Pharmacokinetics
        4.1.3    Adverse Events
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors  
    5.3    Risk Assessment and Treatment Success Rate
6    Global Humira (Adalimumab Drug) Market 
    6.1    Global Humira (Adalimumab Drug) Market Overview
    6.2    Global Humira (Adalimumab Drug) Market Analysis 
        6.2.1    Market Overview
            6.2.1.1    Global Humira (Adalimumab Drug) Market Historical Value (2016-2022) 
            6.2.1.2    Global Humira (Adalimumab Drug) Market Forecast Value (2023-2031)
    6.3    Global Humira (Adalimumab Drug) Market by Indication
        6.3.1    Market Overview
            6.3.1.1    Rheumatoid Arthritis
            6.3.1.2    Ankylosing Spondylitis
            6.3.1.3    Chronic Plaque Psoriasis
            6.3.1.4    Crohn’s Disease
            6.3.1.5    Ulcerative Colitis
            6.3.1.6    Psoriatic Arthritis
            6.3.1.7    Others
    6.4    Global Humira (Adalimumab Drug) Market by Type
        6.4.1    Market Overview
            6.4.1.1    Biologics
            6.4.1.2    Biosimilars
                6.4.1.2.1    Adalimumab-ATTO
                6.4.1.2.2    Adalimumab-BWWD
                6.4.1.2.3    Adalimumab-ADBM
                6.4.1.2.4    Adalimumab-ADAZ
                6.4.1.2.5    Adalimumab-FKJP
                6.4.1.2.6    Adalimumab-AFZB
                6.4.1.2.7    Others
    6.5    Global Humira (Adalimumab Drug) Market by Dosage Strength
        6.5.1    Market Overview
            6.5.1.1    40MG/0.4ML
            6.5.1.2    80MG/0.8ML
            6.5.1.3    20MG/0.4ML
            6.5.1.4    10MG/0.1ML
            6.5.1.5    Others
    6.6    Global Humira (Adalimumab Drug) Market by Drug Type
        6.6.1    Market Overview
            6.6.1.1    Branded
            6.6.1.2    Generics
                6.6.1.2.1    Amjevita
                6.6.1.2.2    Hyrimoz
                6.6.1.2.3    Hulio
                6.6.1.2.4    Others
    6.7    Global Humira (Adalimumab Drug) Market by Route of Administration
        6.7.1    Market Overview
            6.7.1.1    Parenteral
            6.7.1.2    Oral
            6.7.1.3    Others
    6.8    Global Humira (Adalimumab Drug) Market by Distribution Channels
        6.8.1    Market Overview
            6.8.1.1    Hospital Based Pharmacies
            6.8.1.2    Online Pharmacies
            6.8.1.3    Retail Pharmacies
    6.9    Global Humira (Adalimumab Drug) Market by Region
        6.9.1    Market Overview
            6.9.1.1    North America
            6.9.1.2    Europe 
            6.9.1.3    Asia Pacific
            6.9.1.4    Latin America
            6.9.1.5    Middle East and Africa
        6.9.2    North America
            6.9.2.1    Historical Trend (2016-2022)
            6.9.2.2    Forecast Trend (2023-2031)
            6.9.2.3    Break Up by Country
                6.9.2.3.1    United States of America
                6.9.2.3.2    Canada
        6.9.3    Europe
            6.9.3.1    Historical Trend (2016-2022)
            6.9.3.2    Forecast Trend (2023-2031)
            6.9.3.3    Break Up by Country
                6.9.3.3.1    United Kingdom
                6.9.3.3.2    Germany
                6.9.3.3.3    France
                6.9.3.3.4    Italy
                6.9.3.3.5    Others
        6.9.4    Asia Pacific
            6.9.4.1    Historical Trend (2016-2022)
            6.9.4.2    Forecast Trend (2023-2031)
            6.9.4.3    Break Up by Country
                6.9.4.3.1    China
                6.9.4.3.2    Japan
                6.9.4.3.3    India
                6.9.4.3.4    ASEAN
                6.9.4.3.5    Australia
                6.9.4.3.6    Others
        6.9.5    Latin America
            6.9.5.1    Historical Trend (2016-2022)
            6.9.5.2    Forecast Trend (2023-2031)
            6.9.5.3    Break Up by Country
                6.9.5.3.1    Brazil
                6.9.5.3.2    Argentina
                6.9.5.3.3    Mexico
                6.9.5.3.4    Others
        6.9.6    Middle East and Africa
            6.9.6.1    Historical Trend (2016-2022)
            6.9.6.2    Forecast Trend (2023-2031)
            6.9.6.3    Break Up by Country
                6.9.6.3.1    Saudi Arabia
                6.9.6.3.2    United Arab Emirates
                6.9.6.3.3    Nigeria
                6.9.6.3.4    South Africa
                6.9.6.3.5    Others
7    Current Scenario Evaluation and Regulatory Framework
    7.1    Emerging Therapies and Clinical Trials Synopsis
    7.2    Patent Landscape
        7.2.1    Patent Overview
            7.2.1.1    Patent Status and Expiry
            7.2.1.2    Timelines from Drug Development to Commercial Launch
            7.2.1.3    New Drug Application
            7.2.1.3.1    Documentation and Approval Process
    7.3    Cost of Treatment
    7.4    Investment Scenarios
    7.5    Regulatory Framework
        7.5.1    Regulatory Overview
            7.5.1.1    US FDA
            7.5.1.2    EU EMA
            7.5.1.3    INDIA CDSCO
            7.5.1.4    JAPAN PMDA
            7.5.1.5    Others
8    Challenges and Unmet Need
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Rate
    8.3    Awareness and Prevention Gaps
9    Global Humira (Adalimumab Drug) Market Dynamics
    9.1    Market Drivers and Constraints
    9.2    SWOT Analysis
    9.3    Drug Adoption Parameters
    9.4    Porter’s Five Forces Model
    9.5    Key Demand Indicators
    9.6    Key Price Indicators 
    9.7    Value Chain Analysis
10    Supplier Landscape
    10.1    AbbVie Inc.
        10.1.1    Company Overview
        10.1.2    Product Portfolio
        10.1.3    Demographic Reach and Achievements
        10.1.4    Mergers and Acquisitions
        10.1.5    Certifications
    10.2    Amgen Inc.
        10.2.1    Company Overview
        10.2.2    Product Portfolio
        10.2.3    Demographic Reach and Achievements
        10.2.4    Mergers and Acquisitions
        10.2.5    Certifications
    10.3    Fresenius Kabi AG 
        10.3.1    Company Overview
        10.3.2    Product Portfolio
        10.3.3    Demographic Reach and Achievements
        10.3.4    Mergers and Acquisitions
        10.3.5    Certifications
    10.4    Celltrion Healthcare Co Ltd
        10.4.1    Company Overview
        10.4.2    Product Portfolio
        10.4.3    Demographic Reach and Achievements
        10.4.4    Mergers and Acquisitions
        10.4.5    Certifications
    10.5    Alvotech Ehf.
        10.5.1    Company Overview
        10.5.2    Product Portfolio
        10.5.3    Demographic Reach and Achievements
        10.5.4    Mergers and Acquisitions
        10.5.5    Certifications
    10.6    Bio-Thera Solutions Ltd.
        10.6.1    Company Overview
        10.6.2    Product Portfolio
        10.6.3    Demographic Reach and Achievements
        10.6.4    Mergers and Acquisitions
        10.6.5    Certifications
    10.7    Zydus Lifesciences Limited
        10.7.1    Company Overview
        10.7.2    Product Portfolio
        10.7.3    Demographic Reach and Achievements
        10.7.4    Mergers and Acquisitions
        10.7.5    Certifications
    10.8    Hetero Healthcare Ltd.
        10.8.1    Company Overview
        10.8.2    Product Portfolio
        10.8.3    Demographic Reach and Achievements
        10.8.4    Mergers and Acquisitions
        10.8.5    Certifications
    10.9    Innovent Biologics, Inc.
        10.9.1    Company Overview
        10.9.2    Product Portfolio
        10.9.3    Demographic Reach and Achievements
        10.9.4    Mergers and Acquisitions
        10.9.5    Certifications
    10.10    Novartis International AG (Sandoz)
        10.10.1    Company Overview
        10.10.2    Product Portfolio
        10.10.3    Demographic Reach and Achievements
        10.10.4    Mergers and Acquisitions
        10.10.5    Certifications
    10.11    Reliance Life Sciences Pvt. Ltd.
        10.11.1    Company Overview
        10.11.2    Product Portfolio
        10.11.3    Demographic Reach and Achievements
        10.11.4    Mergers and Acquisitions
        10.11.5    Certifications
    10.12    Samsung C&T Corporation
        10.12.1    Company Overview
        10.12.2    Product Portfolio
        10.12.3    Demographic Reach and Achievements
        10.12.4    Mergers and Acquisitions
        10.12.5    Certifications
    10.13    Terumo Corp.
        10.13.1    Company Overview
        10.13.2    Product Portfolio
        10.13.3    Demographic Reach and Achievements
        10.13.4    Mergers and Acquisitions
        10.13.5    Certifications
    10.14    Torrent Pharmaceuticals Ltd.
        10.14.1    Company Overview
        10.14.2    Product Portfolio
        10.14.3    Demographic Reach and Achievements
        10.14.4    Mergers and Acquisitions
        10.14.5    Certifications
11    Recommendations and Discussion 
12    Pricing Models and Strategies (Additional Insight)

    12.1    Cost Model 
        12.1.1    Manufacturing Cost Analysis 
        12.1.2    Procurement Cost Analysis 
    12.2    Pricing Strategies 
        12.2.1    Competitor Pricing Analysis 
        12.2.2    Key Assessment of Product Attributes 
        12.2.3    Pricing Benchmark 
13    Global Humira (Adalimumab) Drug Distribution Model (Additional Insight)
    13.1    Overview
    13.2    Potential Distributors
    13.3    Key Parameters for Distribution Partner Assessment

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The prevalence rate of global HUMIRA (Adalimumab drug) market is likely to grow at a CAGR of 1% during the forecast period of 2023-2031.

Asia Pacific region has the highest growth rate in the HUMIRA (Adalimumab drug) market.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market.

North America dominated the HUMIRA (Adalimumab drug) market and is expected to grow during the forecast period due to excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.

AbbVie Inc., Amgen Inc., Fresenius Kabi AG, Celltrion Healthcare Co Ltd, Alvotech Ehf., Bio-Thera Solutions Ltd., Cadila Healthcare Ltd., Hetero Healthcare Ltd., Innovent Biologics, Inc., Novartis International AG are the key companies in the  global HUMIRA (Adalimumab drug) market.

The factors stimulating the development of the market include increased government initiatives, optimal costs, and a rise in R&D expenditure in biopharmaceutical companies.

The high cost of clinical trials and research and development represents a major challenge for market participants. Despite heavy R&D spending, manufacturers must keep their products low, which limits growth opportunities in the HUMIRA market.

IBI303 and CT-P17 are the emerging drugs that will appear in the market

HUMIRA is a medicine used to treat ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ulcerative colitis, hidradenitis suppurativa and other diseases affecting the musculoskeletal system.

Purchase Full Report

Mini Report

$2499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$6499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$7999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER